(reported by the Company)
ResApp is developing digital healthcare solutions to assist doctors and empower patients to diagnose and manage respiratory disease.
We will provide telehealth companies with point of care diagnostic solutions that can be easily integrated into their platforms.
We are working on apps to provide instant clinical quality diagnostic tests and management tools directly to consumers and healthcare providers.
|Category:||Consumer goods, Health & biotech|
|ASX Listing Code (if applicable):||RAP|
|Year of Commencement:|
Level 24, 44 St Georges Terrace
|Twitter:||Tweets by @resapphealth|
|Current Period Rank:|
|WA Annual Rank 2016:||4|
Demonstrated succes in diagnosing chronic obstructive pulmonary disease and aggravations of COPD
Appointed Nathan Buzza as non-executive director
Appointed Dr Philip Currie to its scientific advisory board
Signed a licensing agreement with UniQuest, the main commercialization company of The University of Queensland
Received its first institutional review board (IRB) approval for the SMARTCOUGH-C study
Presented at Tech23 2016 in Sydney
Received its first institutional review board approval for its SMARTCOUGH-C study
Won the Innovation Excellence Award at Tech 23
Received $516k tax refund from R&D tax incentive
NOTE: Company News, Milestones and Funding are as collected by Techboard as part of our Monthly Startup Ranking
|Type of capital raise:|
|Investment Phone:||Investment phone:|